IgA nephropathy, susceptibility to, 1
Rare disease
No
- Genetic basis
- Yes
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- IgA nephropathy, susceptibility to, 1
- IgA nephropathy, susceptibility to, 1
- IGAN1
- IgA nephropathy, susceptibility to, 1
- glomerulonephritis, IgA
- Severity
- Unknown
- MONDO ID
- MONDO:0008072
- Parent condition
- MONDO:0100555
Related records
Broader conditions (3)
- Disease susceptibility
- IgA nephropathy, susceptibility to
- Inherited disease susceptibility
Trials (262)
- "Steroids and Azathioprine Versus Steroids Alone in IgAN"
- A Clinical Research on the Use of Fecal Bacteria Transplantation for Treatment of IgA Nephropathy
- A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases
- A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases
- A Clinical Study to Evaluate the Effect of Food on the Pharmacokinetic Profiles of HRS-5965 Capsules in Healthy Subjects
- A Controlled Study of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes.
- A Controlled Study of Uric Acid on the Progression of IgA Nephropathy
- A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects
- A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US
- A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy
- A Phase 1 Study of CLYM116 in Normal Healthy Volunteers
- A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
- A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
- A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy
- A Phase IIa Study in Primary IgA Nephropathy Patients
- A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy
- A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy
- A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
- A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept
- A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications